CN120239602A - 伊布莫仑的可压实口服制剂 - Google Patents

伊布莫仑的可压实口服制剂 Download PDF

Info

Publication number
CN120239602A
CN120239602A CN202280101646.1A CN202280101646A CN120239602A CN 120239602 A CN120239602 A CN 120239602A CN 202280101646 A CN202280101646 A CN 202280101646A CN 120239602 A CN120239602 A CN 120239602A
Authority
CN
China
Prior art keywords
day
solid form
tablet
ibuproman
pharmaceutical solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280101646.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·B·帕里克
J·C·麦克韦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Publication of CN120239602A publication Critical patent/CN120239602A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280101646.1A 2022-11-03 2022-11-22 伊布莫仑的可压实口服制剂 Pending CN120239602A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263422329P 2022-11-03 2022-11-03
US63/422,329 2022-11-03
PCT/US2022/050700 WO2024096892A1 (en) 2022-11-03 2022-11-22 Compactable oral formulations of ibutamoren

Publications (1)

Publication Number Publication Date
CN120239602A true CN120239602A (zh) 2025-07-01

Family

ID=90835855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280101646.1A Pending CN120239602A (zh) 2022-11-03 2022-11-22 伊布莫仑的可压实口服制剂

Country Status (12)

Country Link
US (2) US11969416B1 (enExample)
EP (1) EP4611737A1 (enExample)
JP (2) JP7872443B2 (enExample)
KR (1) KR20250107210A (enExample)
CN (1) CN120239602A (enExample)
AU (1) AU2022485048A1 (enExample)
CL (1) CL2025001309A1 (enExample)
CO (1) CO2025007025A2 (enExample)
GE (1) GEAP202516774A (enExample)
IL (1) IL320529A (enExample)
MX (1) MX2025005154A (enExample)
WO (1) WO2024096892A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
JPH11513989A (ja) 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進薬の湿式造粒製剤
CA2420535A1 (en) * 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
ES2710665T3 (es) * 2006-03-15 2019-04-26 Michael O Thorner Métodos para el tratamiento de la sarcopenia con un secretagogo de hormona de crecimiento
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
CA2889499C (en) * 2012-10-24 2019-09-10 Daiichi Sankyo Company, Limited Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
MX378261B (es) * 2013-03-14 2025-03-10 Redhill Biopharma Ltd Formas de dosificación sólidas de liberación prolongada antieméticas.
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
EP4467158A3 (en) * 2018-02-14 2025-02-19 Lumos Pharma, Inc. Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THERESIA KUNTZ等: "Increased compactibility of acetames after roll compaction", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 12 December 2010 (2010-12-12) *
吴正红等主编: "《药剂学》", vol. 2020, 30 April 2020, 中国医药科技出版社, pages: 195 *

Also Published As

Publication number Publication date
US12390452B2 (en) 2025-08-19
US20240156793A1 (en) 2024-05-16
US11969416B1 (en) 2024-04-30
JP2025535941A (ja) 2025-10-30
IL320529A (en) 2025-06-01
JP7872443B2 (ja) 2026-06-09
KR20250107210A (ko) 2025-07-11
EP4611737A1 (en) 2025-09-10
JP2026027432A (ja) 2026-02-18
AU2022485048A1 (en) 2025-05-22
WO2024096892A1 (en) 2024-05-10
CO2025007025A2 (es) 2025-07-17
CL2025001309A1 (es) 2025-09-26
MX2025005154A (es) 2025-07-01
US20240245663A1 (en) 2024-07-25
GEAP202516774A (en) 2025-06-25

Similar Documents

Publication Publication Date Title
AU2016208417B2 (en) Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
US20210315900A1 (en) Solid dosage forms of palbociclib
US6419954B1 (en) Tablets and methods for modified release of hydrophilic and other active agents
AU2014265327B2 (en) Cenicriviroc compositions and methods of making and using the same
CN102085201B (zh) 阿替洛尔和氨氯地平的双层片剂
TW201022253A (en) Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
US20160000721A1 (en) Gastro-retentive formulations
EP3411018A1 (en) Galenic formulations of organic compounds
JP2026027432A (ja) イブタモレンの圧縮型経口製剤
US20050118256A1 (en) Extended release alpha-2 agonist pharmaceutical dosage forms
EP3697392B1 (en) Tablets comprising tamsulosin and solifenacin
CN118416004A (zh) 一种布立西坦双释三层片及其制备方法
WO2022228735A1 (en) Pharmaceutical composition comprising a combination of sitagliptin and metformin and method of preparation thereof
CN115835859A (zh) 包括西他列汀和达格列净的复合制剂以及其制备方法
US20250332149A1 (en) Piperidine compounds and pharmaceutical compositions
US20260041641A1 (en) Novel formulation
EP4512392A2 (en) Orally-administered preparation containing solifenacin and tamsulosin
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
KR20180089811A (ko) 프레가발린 함유 고팽윤성 서방성 삼중정제
HK1214171B (en) Cenicriviroc compositions and methods of making and using the same
HK1190064B (en) Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate
OA17316A (en) Therapeutic compositions comprising Rilpivirine HCL and Tenofovir Disoproxil Fumarate.
HK1220139B (en) Orally disintegrating tablet

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124879

Country of ref document: HK